Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of pelacarsen in healthy volunteers with elevated Lp(a)
NCT02414594Phase 1Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Apr 2015
- Primary completion
- Feb 2016
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Hyperlipoproteinemia a comparing Pelacarsen with Placebo (2 arms). Primary endpoints: Incidence, severity, and dose-relationship of adverse effects and changes in laboratory parameters up to 113 days, Pharmacokinetics of single and multiple doses of IONIS-APO(a)-LRx up to 113 days and 1 more. Started Apr 2015; status: completed.
02
Drugs
pelacarsen
03
Conditions
Hyperlipoproteinemia a
Beyond the preview
Go deeper on NCT02414594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02414594.